Key result
Diabetes confers an increased risk of cardiovascular disease and a dismal prognosis after acute coronary events, necessitating extensive treatment of risk factors and evidence-based therapies.
Diabetes remains a potent cardiovascular risk factor requiring comprehensive management with evidence-based therapies, including novel glucose-lowering drugs that offer cardiovascular benefits beyond glycemic control.
Persistent excess CV risk post-ACS in diabetes demands intensified multifactorial therapy; leaves optimal strategies open.
This review highlights the increased risk of cardiovascular disease and the dismal prognosis after acute coronary events when diabetes is present. Although there have been improvements in this area, diabetes still confers an increased risk. In order to achieve successful outcomes in individuals with diabetes, extensive treatment of risk factors and the use of all available evidence-based therapies are needed. In this context, glucose-lowering therapies and antithrombotic and revascularisation strategies are detailed in this review. Emerging data indicate that novel glucose-lowering drugs may impact cardiovascular outcome with mechanisms that are beyond glucose control. In addition, this review addresses hidden diabetes and impaired glucose tolerance in patients with acute and stable coronary artery disease and how they influence future cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
Norhammar et al. (2017) conducted a review in Diabetes and cardiovascular disease. Diabetes was evaluated. Diabetes confers an increased risk of cardiovascular disease and a dismal prognosis after acute coronary events, necessitating extensive treatment of risk factors and evidence-based therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: